CyBorD
Showing 1 - 18 of 18
Multiple Myeloma, Renal Failure Trial in Augusta (Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide,
Not yet recruiting
- Multiple Myeloma
- Renal Failure
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
-
Augusta, GeorgiaGeorgia Cancer Center-Augusta University
Nov 16, 2023
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance Trial in United States (Cyclophosphamide, Bortezomib,
Recruiting
- Multiple Myeloma
- Monoclonal Gammopathy of Renal Significance
- Cyclophosphamide
- +3 more
-
Basking Ridge, New Jersey
- +6 more
Oct 16, 2023
Multiple Myeloma Trial in Canada (Isatuximab)
Recruiting
- Multiple Myeloma
- Isatuximab
-
Edmonton, Alberta, Canada
- +9 more
Feb 14, 2022
Light Chain (AL) Amyloidosis Trial in Worldwide (Birtamimab, Placebo, Standard of Care Chemotherapy)
Recruiting
- Light Chain (AL) Amyloidosis
- Birtamimab
- +2 more
-
Hartford, Connecticut
- +120 more
Aug 8, 2022
Amyloidosis, Light Chain (AL) Amyloidosis Trial (Bendamustine Hydrochloride, Isatuximab)
Withdrawn
- Amyloidosis
- Light Chain (AL) Amyloidosis
- Bendamustine Hydrochloride
- Isatuximab
- (no location specified)
Dec 29, 2022
AL Amyloidosis Trial in Scottsdale, Jacksonville, Rochester (procedure, biological, other)
Not yet recruiting
- AL Amyloidosis
- Bone Marrow Biopsy
- +4 more
-
Scottsdale, Arizona
- +2 more
Jun 2, 2023
Multiple Myeloma Trial in United States (bb2121, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Multiple Myeloma
- bb2121
- +3 more
-
Scottsdale, Arizona
- +19 more
Jul 7, 2022
Multiple Myeloma, High-Risk Cancer Trial in Montreal (Bortezomib following nonmyeloablative allogeneic transplant)
Active, not recruiting
- Multiple Myeloma
- High-Risk Cancer
- Bortezomib following nonmyeloablative allogeneic transplant
-
Montreal, Quebec, CanadaHôpital Maisonneuve-Rosemont
Aug 22, 2022
Multiple Myeloma Trial in Montréal (ECT-001 (UM171) expanded cord blood)
Active, not recruiting
- Multiple Myeloma
- ECT-001 (UM171) expanded cord blood
-
Montréal, Quebec, CanadaCIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maiso
Mar 8, 2022
Multiple Myeloma Trial in Galway (Daratumumab, Cyclophosphamide, Bortezomib)
Unknown status
- Multiple Myeloma
- Daratumumab
- +3 more
-
Galway, IrelandGalway University Hospital
Mar 27, 2018
Amyloidosis; Systemic Trial in Beijing (Doxycycline, Bortezomib, Cyclophosphamide)
Completed
- Amyloidosis; Systemic
- Doxycycline
- +3 more
-
Beijing, ChinaPeking Union Medical College Hospital
Feb 19, 2021
Myeloma Multiple Trial in Siena (Daratumumab)
Recruiting
- Myeloma Multiple
-
Siena, ItalyAzienda Ospedaliera Universitaria Senese
Jun 17, 2019
Multiple Myeloma Trial in Guangzhou (Cyclophosphamide, Bortezomib, Dexamethasone)
Unknown status
- Multiple Myeloma
- Cyclophosphamide
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen university cancer center
Apr 18, 2016
Amyloidosis Trial in Boston, Cambridge, London (GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb))
Terminated
- Amyloidosis
- GSK2315698 (CPHPC)
- GSK2398852 (anti-SAP mAb)
-
Boston, Massachusetts
- +2 more
Sep 25, 2019
Multiple Myeloma and Plasma Cell Tumor Trial in Scottsdale, Toronto (bortezomib, cyclophosphamide, dexamethasone)
Completed
- Multiple Myeloma and Plasma Cell Neoplasm
- bortezomib
- +2 more
-
Scottsdale, Arizona
- +1 more
May 13, 2011